ML281 Does Not Function as an STK33 Inhibitor but Modulates Proliferation and Differentiation of Keratinocytes Derived from Hypertrophic Scars
Ya Xin Zheng, Hui Song Cui, You Ra Lee, So Young Joo, Yoon Soo Cho, In Suk Kwak, Cheong Hoon Seo · 2026
Read ML281 Does Not Function as an STK33 Inhibitor but Modulates Proliferation and Differentiation of Keratinocytes Derived from Hypertrophic Scars by Ya Xin Zheng, Hui Song Cui, You Ra Lee, So Young Joo, Yoon Soo Cho, In Suk Kwak, Cheong Hoon Seo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13607888.txt.
Description
Ya Xin Zheng and six co-authors report a 2026 study that finds a drug called ML281 does not, in fact, block the kinase STK33 as first thought. The drug was made for that target, which had drawn interest in cancer work. Its role in burn scars was not clear, though.
The team grew skin cells from post-burn hypertrophic scars, where growth and maturity of such cells must stay in balance for skin health. ML281 was added to the cells. Read-outs covered growth marks, scar-linked keratins, and signs of a shift in cell type. The drug did change growth and maturity, but not by the named path.
Catalog record
| CREATOR | Ya Xin Zheng, Hui Song Cui, You Ra Lee, So Young Joo, Yoon Soo Cho, In Suk Kwak, Cheong Hoon Seo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |